GILEAD SCIENCES (GIS DU) stock market data APIs
€125.0577
0.01(0%)
as of September 10, 2026
Try our APIs with
free plan!
GILEAD SCIENCES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.DU.
Prev. Close
125.0577
Open
125.0683
High
125.2212
Low
124.7847
52 wk Range
91.2614-130.1133
Market Cap
78 028 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES data using free add-ons & libraries
Get GILEAD SCIENCES Fundamental Data
GILEAD SCIENCES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES News
New
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix Therapeutics NRIX continues to make steady progress with bexobrutideg, the company's lead product candidate and primary clinical value driver. Nurix is developing bexobrutideg as an oral, brain-...
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Bristol Myers Squibb BMY announced positive phase II results from the registrational QUINTESSENTIAL study evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) in heavily pretreated patients with...
Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
MENLO PARK, Calif., September 09, 2026--(BUSINESS WIRE)--Sofinnova Investments, a biopharmaceutical investment firm, announced today the addition of Merdad Parsey, M.D., Ph.D., to the investment team ...
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed dow...
Get GILEAD SCIENCES fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
